We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

236 hedge funds and large institutions have $3.87B invested in Ultragenyx Pharmaceutical in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 94 increasing their positions, 75 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 23

54% more capital invested

Capital invested by funds: $2.52B → $3.87B (+$1.36B)

25% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 75

8% more funds holding

Funds holding: 219 → 236 (+17)

0.1% less ownership

Funds ownership: 98.74% → 98.64% (-0.1%)

1% less call options, than puts

Call options by funds: $23.1M | Put options by funds: $23.4M

40% less funds holding in top 10

Funds holding in top 10: 5 → 3 (-2)

Holders
236
Holders Change
+17
Holders Change %
+7.76%
% of All Funds
3.44%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.04%
New
44
Increased
94
Reduced
75
Closed
23
Calls
$23.1M
Puts
$23.4M
Net Calls
-$285K
Net Calls Change
-$1.62M

Top Buyers

1
Sands Capital Management
Sands Capital Management
Virginia
+$59.7M
2
RI
RTW Investments
New York
+$57.5M
3
SCM
Suvretta Capital Management
New York
+$56.1M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$55.8M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$36.2M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$44.6M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$30.3M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$23.8M
4
FLAM
First Light Asset Management
Minnesota
-$14.7M
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$9.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
S
226
Sachetta
Massachusetts
$1.53K +$1.24K +32 New
PA
227
Parallel Advisors
California
$1.48K -$9.23K -238 -88%
CTC
228
Central Trust Company
Missouri
$1.15K – – –
JWM
229
Janiczek Wealth Management
Colorado
$957 +$775 +20 New
MPWT
230
MassMutual Private Wealth & Trust
Connecticut
$861 – – –
SRCM
231
Signature Resources Capital Management
California
$717 +$582 +15 New
BIA
232
Bell Investment Advisors
California
$527 – – –
Northwestern Mutual Wealth Management
233
Northwestern Mutual Wealth Management
Wisconsin
$478 -$3.49K -90 -90%
AF
234
Allworth Financial
California
$335 -$1.28K -33 -83%
ASN
235
Advisory Services Network
Georgia
$48 +$39 +1 New
FFA
236
Farther Finance Advisors
California
$48 +$39 +1 New
IC
237
Ikarian Capital
Texas
– -$6.24M -174,945 Closed
Bank of Nova Scotia
238
Bank of Nova Scotia
Ontario, Canada
– -$1.51M -42,451 Closed
BFM
239
Boothbay Fund Management
New York
– -$1.34M -37,591 Closed
N
240
Natixis
France
– -$1.18M -33,100 Closed
AA
241
AlphaCentric Advisors
Puerto Rico
– -$1.07M -30,000 Closed
CSS
242
Cubist Systematic Strategies
Connecticut
– -$1.04M -29,178 Closed
JF
243
Jump Financial
Illinois
– -$835K -23,436 Closed
YIH
244
Y-Intercept (HK)
Hong Kong
– -$551K -15,442 Closed
HS
245
HighVista Strategies
Massachusetts
– -$520K -14,591 Closed
ACM
246
Aquatic Capital Management
Illinois
– -$456K -12,800 Closed
DnB Asset Management
247
DnB Asset Management
Norway
– -$452K -12,674 Closed
CC
248
Corton Capital
Ontario, Canada
– -$316K -8,856 Closed
PMEF
249
Point72 Middle East FZE
United Arab Emirates
– -$258K -7,243 Closed
AIM
250
Aigen Investment Management
New York
– -$240K -6,732 Closed
7 8 9
10
11

RARE Hedge Fund Activity: Q4 2023 in Review

236 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2023, worth a combined $3.87B — up 54% from $2.52B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new RARE positions and 23 closed out — a net gain of 21 holders — while 94 added to existing stakes and 75 trimmed.

The largest buyer was Sands Capital Management, adding an estimated $59.7M. The largest seller was Avoro Capital Advisors, cutting an estimated $44.6M.

  • 236 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2023, up from 219 in Q3 2023.
  • Funds reported $3.87B of Ultragenyx Pharmaceutical stock for Q4 2023, up 54% quarter-over-quarter.
  • 44 funds opened new Ultragenyx Pharmaceutical positions in Q4 2023 and 23 closed out, a net change of +21 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q4 2023 was Sands Capital Management, an estimated $59.7M added.
  • The largest Ultragenyx Pharmaceutical seller in Q4 2023 was Avoro Capital Advisors, an estimated $44.6M sold.

Based on aggregated 13F filings for Q4 2023.